BR0313871A - Derivados aromáticos contendo nitrogênio - Google Patents
Derivados aromáticos contendo nitrogênioInfo
- Publication number
- BR0313871A BR0313871A BR0313871-2A BR0313871A BR0313871A BR 0313871 A BR0313871 A BR 0313871A BR 0313871 A BR0313871 A BR 0313871A BR 0313871 A BR0313871 A BR 0313871A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- group
- optionally substituted
- nitrogen
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
"DERIVADOS AROMáTICOS CONTENDO NITROGêNIO". A presente invenção refere-se a um composto representado pela fórmula geral: em que X~ 1~ representa um átomo de nitrogênio ou um grupo representado pela fórmula -CR~ 10~=, X~ 2~ representa um átomo de nitrogênio ou um grupo representado pela fórmula -CR~ 11~=; Y representa um átomo de oxigênio ou similares; R~ 1~, representa um grupo de alcóxi C~ 1-6~, um grupo de arilóxi C~ 6-10~ opcionalmente substituído, um grupo representado pela fórmula -NR~ 12a~,R~ 12b~ ou similares; R~ 2~ representa um átomo de hidrogênio, um grupo de alquila C~ 1-6~ opcionalmente substituído, ou similares; R~ 3~, R~ 4~, R~ 5~, R~ 6~, R~ 7~, R~ 8~, R~ 10~ e R~ 11~ cada um independentemente representa um átomo de hidrogênio, um átomo de halogênio, um grupo de alquila C~ 1-6~ opcionalmente substituído, ou similares; R~ 9~ representa um grupo representado pela fórmula -NR~ 16a~R~ 16b~ ou similares; R~ 12a~, R~ 12b~, R~ 16a~ e R~ 16b~ cada um independentemente representa um átomo de hidrogênio, um grupo de alquila C~ 1-6~ opcionalmente substituído, ou similares, um sal destes, ou um hidrato dos precedentes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002253123 | 2002-08-30 | ||
US46469003P | 2003-04-22 | 2003-04-22 | |
PCT/JP2003/010964 WO2004020434A1 (ja) | 2002-08-30 | 2003-08-28 | 含窒素芳香環誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313871A true BR0313871A (pt) | 2005-07-19 |
Family
ID=31980530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313871-2A BR0313871A (pt) | 2002-08-30 | 2003-08-28 | Derivados aromáticos contendo nitrogênio |
Country Status (15)
Country | Link |
---|---|
US (3) | US20060004029A1 (pt) |
EP (1) | EP1522540A4 (pt) |
JP (1) | JP4183193B2 (pt) |
KR (1) | KR100732440B1 (pt) |
CN (1) | CN100339376C (pt) |
AU (1) | AU2003261807B9 (pt) |
BR (1) | BR0313871A (pt) |
CA (1) | CA2488739A1 (pt) |
IL (1) | IL165762A0 (pt) |
MX (1) | MXPA05001536A (pt) |
NO (1) | NO20051577L (pt) |
NZ (1) | NZ538617A (pt) |
RU (1) | RU2310651C2 (pt) |
TW (1) | TW200413353A (pt) |
WO (1) | WO2004020434A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
EP1817025A2 (en) * | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
KR100990590B1 (ko) * | 2005-09-01 | 2010-10-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 붕해성이 개선된 의약 조성물의 제조 방법 |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
CN101443009A (zh) * | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
JPWO2008001956A1 (ja) | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
WO2008026748A1 (fr) * | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
CA2676796C (en) * | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
PT2154967E (pt) * | 2007-04-16 | 2014-06-05 | Hutchison Medipharma Entpr Ltd | Derivados de pirimidina |
US7889523B2 (en) * | 2007-10-10 | 2011-02-15 | Freescale Semiconductor, Inc. | Variable load, variable output charge-based voltage multipliers |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
CN102186822A (zh) * | 2008-08-29 | 2011-09-14 | 顶标公司 | 新脲和硫脲衍生物 |
JO3265B1 (ar) * | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
EP2700403B1 (en) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
EP2546624B1 (en) | 2011-07-15 | 2017-11-29 | GEA Food Solutions Bakel B.V. | Heat-treatment device comprising a shielded microwave-radiometry-antenna |
AU2013337297A1 (en) | 2012-11-05 | 2015-05-21 | Nantbio, Inc. | Substituted indol-5-ol derivatives and their therapeutical applications |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
CA2906185A1 (en) | 2013-03-15 | 2014-09-18 | Nantbioscience, Inc. | Substituted indol-5-ol derivatives and their therapeutic applications |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 4−アミノピリジン誘導体 |
RU2658821C1 (ru) * | 2014-08-18 | 2018-06-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль моноциклического производного пиридина и ее кристалл |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
PL3200786T3 (pl) * | 2014-10-03 | 2020-03-31 | Novartis Ag | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 |
PT3263106T (pt) | 2015-02-25 | 2024-01-12 | Eisai R&D Man Co Ltd | Método para suprimir o amargor do derivado de quinolina |
AU2015383881B2 (en) | 2015-02-27 | 2021-01-28 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
EP3777860A4 (en) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA |
JP2023507570A (ja) | 2019-12-19 | 2023-02-24 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物および方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
ES2318649T3 (es) * | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
US7238813B2 (en) * | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
-
2003
- 2003-08-28 WO PCT/JP2003/010964 patent/WO2004020434A1/ja active IP Right Grant
- 2003-08-28 RU RU2005108999/04A patent/RU2310651C2/ru not_active IP Right Cessation
- 2003-08-28 NZ NZ538617A patent/NZ538617A/en unknown
- 2003-08-28 BR BR0313871-2A patent/BR0313871A/pt not_active IP Right Cessation
- 2003-08-28 KR KR1020057003337A patent/KR100732440B1/ko not_active IP Right Cessation
- 2003-08-28 JP JP2004532761A patent/JP4183193B2/ja not_active Expired - Fee Related
- 2003-08-28 AU AU2003261807A patent/AU2003261807B9/en not_active Ceased
- 2003-08-28 EP EP03791389A patent/EP1522540A4/en not_active Withdrawn
- 2003-08-28 CN CNB038202719A patent/CN100339376C/zh not_active Expired - Fee Related
- 2003-08-28 CA CA002488739A patent/CA2488739A1/en not_active Abandoned
- 2003-08-28 MX MXPA05001536A patent/MXPA05001536A/es active IP Right Grant
- 2003-08-28 US US10/521,074 patent/US20060004029A1/en not_active Abandoned
- 2003-08-29 TW TW092123981A patent/TW200413353A/zh unknown
- 2003-08-29 US US10/651,496 patent/US7109219B2/en not_active Expired - Lifetime
-
2004
- 2004-12-14 IL IL16576204A patent/IL165762A0/xx unknown
-
2005
- 2005-03-29 NO NO20051577A patent/NO20051577L/no not_active Application Discontinuation
-
2006
- 2006-08-18 US US11/507,082 patent/US7468380B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IL165762A0 (en) | 2006-01-15 |
AU2003261807B2 (en) | 2007-01-04 |
EP1522540A4 (en) | 2011-08-10 |
NZ538617A (en) | 2005-12-23 |
US7468380B2 (en) | 2008-12-23 |
MXPA05001536A (es) | 2005-04-19 |
RU2310651C2 (ru) | 2007-11-20 |
US20050187236A1 (en) | 2005-08-25 |
KR20050059151A (ko) | 2005-06-17 |
US7109219B2 (en) | 2006-09-19 |
TW200413353A (en) | 2004-08-01 |
US20060004029A1 (en) | 2006-01-05 |
CN1678607A (zh) | 2005-10-05 |
JPWO2004020434A1 (ja) | 2005-12-15 |
NO20051577L (no) | 2005-05-27 |
AU2003261807A1 (en) | 2004-03-19 |
KR100732440B1 (ko) | 2007-06-27 |
CA2488739A1 (en) | 2004-03-11 |
US20070004764A1 (en) | 2007-01-04 |
EP1522540A1 (en) | 2005-04-13 |
AU2003261807B9 (en) | 2007-02-15 |
CN100339376C (zh) | 2007-09-26 |
JP4183193B2 (ja) | 2008-11-19 |
WO2004020434A1 (ja) | 2004-03-11 |
RU2005108999A (ru) | 2005-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313871A (pt) | Derivados aromáticos contendo nitrogênio | |
NO20023457D0 (no) | Nye piperidinforbindelser og legemidler inneholdende de samme | |
BRPI0408260A (pt) | agente miticida | |
BR0013251A (pt) | Derivado de isoxazolina e herbicida que contém o mesmo como ingrediente ativo | |
DE60123933D1 (de) | Fluoreszierende proben zur quantitativen bestimmung von zink | |
MX2010001240A (es) | Derivado de oxopirazina y herbicida. | |
DK1217001T3 (da) | Quinuclidinforbindelser og lægemidler indeholdende dem som den aktive bestanddel | |
BR0311697A (pt) | Novos derivados condensados de imidazol | |
HK1139381A1 (en) | Bicyclic -amino acid derivative | |
CY1107010T1 (el) | Παραγωγο βενζοϋλπυριδινης ´η αλας αυτης, μυκητοκτονο που περιεχει αυτο σαν δραστικο συστατικο, μεθοδος παρασκευης αυτου και ενδιαμεσο για παρασκευη αυτου | |
BR9900788A (pt) | Compostos ésteres. | |
HK1082498A1 (en) | Chemical intermediate | |
HUP0402235A2 (hu) | 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények | |
IS4834A (is) | ísókínólín gagnleg sem verkjalyf | |
DE60025744D1 (de) | Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1 | |
BR0115210A (pt) | Derivado de pirimidina e produto herbicida contendo o mesmo | |
ATE442363T1 (de) | Verfahren zur herstellung von pyridinverbindungen | |
BR0308483A (pt) | Composto fenólico e material de gravação usando o mesmo | |
DK0870763T3 (da) | Kondenserede piperidinderivater som inhibitorer for syntese af nitrogenmonoxid | |
ATE248814T1 (de) | 16-ene-vitamin d derivate | |
HUP0200144A2 (hu) | Eljárás peszticid hatású 5-amino-1-aril-3-cianopirazol-származékok előállítására és az új köztitermékek | |
DK1325923T3 (da) | Cephem-forbindelser og ESBL-detekterende reagenser indeholdende disse | |
BR9909497A (pt) | Métodos para inibição da mrp1 | |
BR0308935A (pt) | Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida | |
HUP0000966A2 (hu) | Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |